Cigna raises annual profit forecast on strength in health services unit

Cigna beat third-quarter estimates, reporting adjusted revenue of $73.79 billion versus $72.72 billion expected and adjusted earnings of $7.98 per share versus $7.50. It raised its 2026 adjusted-profit forecast by 15 cents to at least $30.60 per share and expects adjusted profit to grow at least 10% in 2027. Growth in insurance and specialty pharmacy was partly offset by a 22% profit decline in pharmacy benefit services and ongoing pressures including ACA-market exits and lower drug rebates.

Analysis

The key signal is mix, not headline growth: specialty pharmacy and care services are offsetting pressure in pharmacy-benefit services, where profit fell. Treat Evernorth revenue growth cautiously—drug and pharmacy flows can inflate revenue without comparable earnings contribution. The test is whether fee-based contracts preserve economics as rebates decline, not whether reported sales keep rising.

The 2027 profit-growth floor and transition costs rolling off create a plausible near-term earnings bridge, but the bridge is conditional: contract repricing must offset lower rebates, less employer coverage of weight-loss drugs, and fewer lower-cost specialty-drug launches. ACA withdrawal at end-2026 should reduce exposure to that book over time, but may bring transition costs and remove revenue; it does not automatically improve consolidated margins. The AI savings target is distant and should receive little valuation credit until savings appear in expenses.

Contrarian angle: the favorable earnings surprise may understate the durability question. Conversely, a modestly higher medical loss ratio is not necessarily a negative surprise when it remains below the cited analyst estimate and was described as priced for; monitor employer-plan experience rather than extrapolating one quarter. Competitive pressure on PBM economics could also benefit specialty-focused rivals, while large integrated peers such as CVS Health and UnitedHealth face their own distinct exposures and are not clean read-throughs.

Key Decisions for Investors

• Consider a measured long in CI on post-results weakness rather than chasing the beat; the thesis is a 2027 earnings inflection as transition costs recede, not near-term revenue acceleration. Reassess if management lowers the 2027 growth floor or fee-based contract economics disappoint.
• Track quarterly pharmacy-benefit profit and specialty pharmacy/care-services profit separately. A continued PBM decline without specialty growth sustaining the offset would falsify the mix-improvement thesis; request evidence on rebate-to-fee contract retention and unit economics.
• Treat the 2030 AI savings program as optional upside, not a current earnings catalyst. Look for disclosed realized savings and implementation expense before underwriting margin expansion.
• Watch employer-plan medical-cost trends, ACA exit costs, and drug-launch/rebate changes over the next 1–3 quarters. A sustained adverse medical-cost trend or weaker 2027 guidance would argue against adding; absent those signals, the ACA exit alone is not a reason to short CI.